This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
GREENWOOD VILLAGE, Colo.,
March 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the closing of its sale of 9,775,000 shares of common stock in an underwritten public offering. The total number of shares of common stock sold reflects the full exercise by the underwriters of their option to purchase an additional 1,275,000 shares of common stock. As a result, Ampio Pharmaceuticals, Inc. has received gross proceeds of approximately
$68 million. Net proceeds, after deducting underwriting discounts and commissions and other estimated fees and expenses payable by Ampio Pharmaceuticals, Inc., will be approximately
Citigroup Global Markets Inc. and Jefferies LLC acted as joint book-running managers for the offering.
The securities described were offered by Ampio Pharmaceuticals, Inc. pursuant to shelf registration statements on Form S-3 (File Nos. 333-177116 and 333-193096) including base prospectuses, previously filed and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement related to the offering was filed with the SEC on
February 24, 2014 and a final prospectus supplement related to the offering was filed with the SEC on
February 28, 2014 and is available on the SEC's website located at
www.sec.gov. Electronic copies of the final prospectus supplement also may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by email at
firstname.lastname@example.org, or by phone at (800) 831-9146; and Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY 10022, or by email at
Prospectus_Department@jefferies.com, or by phone at (877) 547-6340.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.